ArticleAnalytical biochemistry2006
A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers.
Article in Analytical biochemistry, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Integration of a multimeric STAT consensus site into the adenoviral genome to interfere with IFN signaling represents a novel concept to improve oncolytic virotherapy.Journal of virology · 2026Article
- Adenovirus mediated gene therapy in cell lines derived from canine oral melanoma.Frontiers in immunology · 2026Article
- Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade.Molecular therapy. Oncology · 2025Article
- Chromatographic Purification of Viral Vectors for Gene Therapy Applications.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Stable expression of shRNA for the control of recombinant adenovirus replication.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Article
- Article
- Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures.Molecular therapy oncolytics · 2022Article
- A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation.Scientific reports · 2021Article
- Separation, characterization, and standardization of extracellular vesicles for drug delivery applications.Advanced drug delivery reviews · 2021Review
- Exploration of p53 plus interferon-beta gene transfer for the sensitization of human colorectal cancer cell lines to cell death.Cancer biology & therapy · 2021Article
- Combination of epidural electrical stimulation withNeural regeneration research · 2021Article
- Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector.Scientific reports · 2020Article
- Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.Gene therapy · 2020Article
- Extracellular vesicles provide a capsid-free vector for oncolytic adenoviral DNA delivery.Journal of extracellular vesicles · 2020Article
- Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation.Frontiers in immunology · 2020Article
- p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Article
- Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response.British journal of cancer · 2018Article
- Confounding factors of ultrafiltration and protein analysis in extracellular vesicle research.Scientific reports · 2017Article
- Reestablishment of p53/Arf and interferon-Cell death discovery · 2017Article
- Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma.Translational oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Recombinant adenoviral vectors (adenovectors) have been subject to various genetic modifications to improve their transduction efficiency and targeting capacity. Production and purification of adenovectors with modified capsid proteins can be problematic using conventional two-cycle CsCl gradient ultracentrifugation. We have developed a new method for purifying recombinant adenovectors in two steps: iodixanol discontinuous density gradient ultracentrifugation and size exclusion column chromatography. The purity and infectious activity of adenovectors isolated by the two methods were comparable. The new method yielded three to four times more adenovectors with arginine-glycine-aspartic acid (RGD)-modified fiber proteins than did the conventional CsCl method. For other fiber-modified and wild-type adenovectors, the yields of the two methods were comparable. Thus, the iodixanol-based method can be used not only to improve the production of RGD-modified adenovectors but also to purify adenovectors with or without fiber modifications. Moreover, the whole procedure can be completed in 3h. Therefore, this method is rapid and efficient for production of recombination adenovectors, especially those with RGD-modified fibers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.